Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Could Benefit From Bavencio Sales Growth Until 2024

After Pfizer Alliance Exit

Executive Summary

While Q1 earnings were nothing exciting, the German major highlighted that Pfizer’s decisions to return to the rights to Bavencio would boost performance in the near term, although competition from Seagen is on the horizon.

You may also be interested in...



BMS’s Bladder Cancer Program Sees Change In Fortunes With Opdivo Substudy Win

A cohort of patients in CheckMate-901 eligible for cisplatin chemotherapy showed OS and PFS improvements, after the company reported negative results in PD-L1-positive patients last year.

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.

Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel